Celebrex, Bextra To Be Targets Of Public Citizen Withdrawal Petition
This article was originally published in The Pink Sheet Daily
Executive Summary
The watchdog group plans to file a petition in the next week calling for the withdrawal of Pfizer's COX-2 inhibitors. Celebrex and Bextra are among 180 currently marketed drugs Public Citizen advises consumers "do not use" on its expanded worstpills.org website.
You may also be interested in...
Pfizer's Celebrex, Bextra Targets Of Public Citizen Withdrawal Petition
Public Citizen tells FDA that COX-2 inhibitors have inherent cardiovascular risks and offer no efficacy advantages over non-selective NSAIDs. The group suggests the mechanism that creates the COX-2 inhibitors' thrombogenicity is "increased platelet-vessel wall interactions and firm adhesions."
Pfizer's Celebrex, Bextra Targets Of Public Citizen Withdrawal Petition
Public Citizen tells FDA that COX-2 inhibitors have inherent cardiovascular risks and offer no efficacy advantages over non-selective NSAIDs. The group suggests the mechanism that creates the COX-2 inhibitors' thrombogenicity is "increased platelet-vessel wall interactions and firm adhesions."
FDA Drug Safety Initiative Will Include New Website On Rx Risks
The site is intended as an avenue for the agency to disclose safety issues that have not yet been definitively reviewed, and to emphasize the risks with all prescription drugs. The website proposal is understood to be in the internal agency review phase.